Background: Copper-associated hepatopathy (CAH) is a common cause of liver disease
death if left untreated. 1, 2 The disease has garnered considerable attention from the veterinary community in recent years. [3] [4] [5] Once thought to be a rare condition affecting only Bedlington Terriers, CAH is widely recognized in Labrador Retrievers, Doberman Pinschers, West Highland White Terriers, and Dalmatians. [6] [7] [8] [9] [10] [11] More recently, CAH has been recognized in various breeds and crosses not typically considered predisposed to CAH. 4, 12, 13 The genetic basis for disease in Bedlington Terriers is well described, but the etiology in other breeds is complex and multifactorial. 4, [14] [15] [16] The primary goals of treatment are to decrease hepatic copper concentrations ([Cu] H ) and prevent subsequent re-accumulation. Both dietary copper restriction and PO administration of zinc salts can prevent further copper accumulation in some dogs, but these treatments do not quickly affect the copper load already present in the liver. 17, 18 Some dogs develop gastrointestinal upset when treated with high doses of zinc salts, and some dogs continue to accumulate copper despite feeding of a copper-restricted diet. 2, 19 Consequently, these treatments are indicated for dogs with subclinical disease or for maintenance treatment after more aggressive treatment. 1 D-penicillamine is considered the initial treatment of choice for most dogs with CAH including those with clinical illness and those with moderate to severe hepatic histopathologic abnormalities. 1, 2 It is a potent copper chelator that can rapidly induce urinary copper excretion and negative copper balance. 20 However, it is not uniformly effective, and some dogs experience minimal or no decrease in [Cu] H despite months of treatment. 21 Even in dogs that respond to treatment, the duration of treatment necessary to restore normal [Cu] H often exceeds 6-10 months. 22 Anorexia and vomiting are common adverse effects, and in some instances, these can preclude D-penicillamine usage. 2, 23 Although D-penicillamine remains an effective drug for many dogs with CAH, these limitations warrant investigation of alternative treatments.
Ammonium tetrathiomolybdate (TTM) is a copper chelator that has proven to be an effective treatment for Wilson's disease in humans, copper toxicosis in sheep, and pathologic copper accumulation in rodents. [24] [25] [26] This molybdenum salt forms a tight tripartite complex with copper and albumin, most of which then undergoes hepatobiliary excretion. 24 It is unique because of its additive actions in the intestines, plasma, and liver. 27 Administration of TTM to healthy dogs increases serum copper concentrations, which suggests that TTM mobilizes tissue copper. 28 However, the use of TTM to treat dogs with CAH has not been reported. Our objectives were to determine if TTM After study conclusion, dogs were transitioned to standard of care treatments at the discretion of their attending veterinarian.
| Hepatic histopathology and quantitative mineral determinations
Limited assessments of coagulation, including determination of prothrombin and activated partial thromboplastin times, were normal in all dogs before each hepatic biopsy procedure. Ultrasound-guided hepatic biopsies were performed while dogs were under general anesthesia.
For each procedure, 6-7 tissue specimens were collected using a 14- (Table 1) . A validated scoring system for hepatopathology in dogs does not exist, and the scoring system used herein was derived from the same sources used in previous veterinary publications. 22, [34] [35] [36] It closely resembles a scoring system proposed by the World Small Animal Veterinary Association Liver Standardization
Group with the exception that centrilobular inflammation was treated as a distinct category, given the classic pattern of copper accumulation and inflammation in CAH. 31 Briefly, scores were assigned for the severity of fibrosis (range, F0-F4), centrilobular inflammation (range, C0-C3), portal inflammation (range, P0-P3), lobular necrosis (range, LN0-LN2),
and piecemeal necrosis (range, PMN0-PMN3). An overall necroinflammatory activity score (NI) was obtained by adding the scores for centrilobular inflammation, portal inflammation, lobular necrosis, and piecemeal necrosis. Necroinflammatory activity scores could range from 0 to 11.
Rhodanine-stained slides were assessed for copper accumulation using a previously described system with potential scores ranging from 0 (no detected copper granules) to 5 (panlobular presence of large numbers of copper granules in hepatocytes, usually associated with copper-containing macrophages). 30 Quantitative hepatic copper and molybdenum concentrations (μg/g, dry matter basis) were determined on liver specimens using inductively coupled plasma-mass spectroscopy as described elsewhere. 4 Hepatic molybdenum concentrations were measured because they are a potential marker for TTM. 27, 28 The reference intervals in our laboratory for hepatic copper and molybdenum concentrations in dogs are 137-400 μg/g and 0.8-2.3 μg/g, respectively. These reference intervals were established by evaluating the concentrations in all hepatic tissue submissions over a several-year time period and utilizing the 10%-90%
range of obtained values as the normal reference interval. However, the reference interval for copper was modified to be consistent with other laboratories that have adopted 400 μg/g as the upper-end of normal given that rhodanine staining often is positive at this threshold. 
| Clinical monitoring
Oral TTM treatment was well tolerated at the initial dosage in 8 dogs but all dogs were alive >6 months after study completion.
| Clinicopathologic evaluations
Hematologic and serum biochemical evaluations were performed every 2 weeks for study duration ( Table 2 ). Five of 10 dogs (dogs 3, 5, 8, 9, and 10) had decreases in serum ALT activity at week 6 as compared to baseline, but overall changes were not significant (P = .34). Serum ALT activity had increased >2-fold in 2 dogs (dogs 6 and 7) at the time of the week 6 reevaluation. These same 2 dogs did not have decreases in 
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All slides were scored for necroinflammatory activity and fibrosis using the above guidelines. A composite score for necroinflammatory was created by summating the scores for centrilobular inflammation, portal inflammation, lobular necrosis, and piecemeal necrosis with potential scores ranging from 0 to 11.
[Cu] H at week 6, and the study was concluded at this point in both dogs. Mean serum concentrations of bilirubin, cholesterol, albumin, and urea nitrogen, which are potential biochemical markers of liver function, remained within reference intervals for study duration.
| Hepatic mineral concentrations and histologic scores
Treatment with TTM decreased [Cu] H (Figure 1 ). Hepatic copper concentrations (median, range) at week 6 (1033 μg/g, 450-2975 μg/g) and week 12 (931 μg/g, 218-1677 μg/g) were less than [Cu] H at baseline (1606 μg/g, 572-5158 μg/g; P = .04 and P = .02, respectively). At week at baseline or week 12 (P = .14 for both comparisons).
Rhodanine and H&E stained slides were evaluated and scored for each dog. At study conclusion (week 6 for 2 dogs and week 12 for 8 dogs), rhodanine scores were decreased in 6 dogs (dogs 1, 2, 3, 7, 9, and 10) and were unchanged in 4 dogs. Median fibrosis scores were unchanged throughout the study, and no dog had worse scores for fibrosis at study conclusion as compared to baseline. Five dogs (dogs 4, 6, 7, 8, and 9) had worse composite scores for necroinflammatory activity, whereas activity scores were improved (dogs 1 and 3) or unchanged (dogs 3, 5, and 10) in the remaining dogs. A summary of histologic scores for rhodanine, necroinflammatory activity, and fibrosis is presented in Table 3 . Although this decrease was not significant (P = .10), the scores of 3.5, activities and fibrosis scores were unchanged, and although median necroinflammatory activity scores decreased, some individual dogs had worsening necroinflammatory scores. 22 Reasons for the lack of changes in our study are likely complex and multifactorial. The decreases in
| DISCUSSION
[Cu] H were of clinical relevance in most dogs, but they were unlikely to be of the magnitude necessary to completely ameliorate copper-induced hepatocyte injury. 1,2 Many patients with Wilson's disease receiving TTM also experience increased ALT activity during initial treatment, which is thought to be a result of increased copper mobilization during the initial phases of treatment. 39, 40 Similar to our study, serum markers of liver function usually remain normal in these patients. 24, 39, 40 The lack of decrease in histology scores and liver enzyme activities could be perceived as a discouraging finding, but it is important to note that these variables did not worsen. Treatment with TTM may have stabilized disease in some dogs and prevented further progression of liver injury, but this conclusion is speculative pending additional investigation. Values represent the medians, and ranges are provided in parentheses. Rhodanine-stained slides were scored to further assess copper accumulation with potential scores ranging from 0 to 5. Hematoxylin and eosinstained slides were scored for necroinflammatory activity and fibrosis with potential scores ranging from 0 to 11 and 0 to 4, respectively.
in dogs, and continued treatment may not confer additional benefit.
More detailed studies of TTM are needed to address these possibilities and clarify potential roles of TTM for treatment of CAH.
The antagonistic and inverse relationships between molybdenum and copper are well described, and it is possible that TTM efficacy could correlate with tissue molybdenum concentrations. 24 The etiology of CAH in most breeds of dogs is complex and poorly characterized, but dietary copper likely is involved in the pathogenesis.
2-4,15
Dietary copper concentrations were not investigated as part of our study, and it is possible that TTM responsiveness was influenced by dietary cop- sheep. 25 The dosing schedule for TTM may not be practical for some dog owners. This protocol was chosen because it was comparable to those used in humans with Wilson's disease, and it would be most likely to result in a detectable clinical effect. 24, 40 Alternate dosing strategies might lessen compliance concerns and still result in efficacy. Indeed, an experimental formulation of tetrathiomolybdate that requires once daily dosing is currently in development for humans with Wilson's disease. 
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